Myasthenia gravis (MG) is an autoimmune, neuromuscular transmission disease characterized by a fluctuating weakness of skeletal muscle. Our findings highlight the need for additional randomized clinical trials in these patients with MG. There was no difference in mortality between the two treatment options. Of the 165 articles, 64 articles were included for a systematic literature and 11 articles for a meta-analysis.Ĭonclusions: This systematic literature review and meta-analysis of treatment options showed that there was a higher response rate with TPE than IVIG in acute MG patients and patients undergoing thymectomy.
#PLEX TREATMENT FULL#
Among these, 165 full texts articles were reviewed for eligibility and 101 articles were excluded. Results: The search strategy resulted in 535 articles whose abstracts were reviewed. Methods: A systematic literature search for studies published between 19 was performed per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using two database sources, MEDLINE (through the PubMed database) and Cochrane Library. The purpose of this study was to systematically review the literature on the comparative efficacy and safety of TPE to other available treatments for MG. To date, there is no definitive understanding of which of the two treatments is more effective and safer. 3Department of Pathology, University of New Mexico, Albuquerque, NM, United Statesīackground: Patients with Myasthenia Gravis (MG) can be treated acutely with therapeutic plasma exchange (TPE) or intravenous immune globulin (IVIG).2Terumo Blood and Cell Technologies, Lakewood, CO, United States.1Department of Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States.